CD36 and prostate cancer: Thus, VanderWeele and coworkers examined, by exome sequencing, low-grade (GP3) and high-grade (GP4) foci in four prostate cancers and, in two of these cases, metastatic lesions: 87% of somatic mutations observed in GP3 were private to GP3 foci; GP4 and metastatic lesions displayed a high concordance of the mutational profile; GP4 shared only 9% with GP3, but 82% with metastatic lesions [12].